Brian Rini, MD, FASCO
Vanderbilt University Medical Center, Nashville, TN
Brian I. Rini, MD is a Professor of Medicine at Vanderbilt University in Nashville, TN. Dr. Rini is the Chief of Clinical Trials for the Vanderbilt Ingram Cancer Center (VICC).
Dr. Rini earned his medical degree at the Ohio State University College of Medicine in Columbus, Ohio. After completing a residency program in internal medicine at University of Chicago Hospitals in Illinois, Dr. Rini was awarded a fellowship in hematology and oncology at the University of Chicago. Dr. Rini was an Assistant Professor at the University of California San Francisco before moving to Cleveland Clinic in 2005. Dr. Rini led the Genitourinary cancer program at Cleveland Clinic and was integrally involved in drug development in RCC, leading several pivotal trials that led to FDA approval. Dr. Rini moved to Vanderbilt in 2020 to continue his RCC research and oversee clinical trials at the VICC.
Dr. Rini’s primary research has been in renal cell carcinoma (RCC), with special focus on antiangiogenic therapy and immunotherapy. Dr. Rini’s research has been published in peer-reviewed journals that include the New England Journal of Medicine, Journal of the National Cancer Institute, Journal of Clinical Oncology, Lancet and the Journal of the American Medical Association.
Certified in Medical Oncology by the American Board of Internal Medicine, Dr. Rini is active in numerous professional organizations including ASCO, the Society for Immunotherapy of Cancer (SITC), the Kidney Cancer Association (KCA) and is past Chair of the Oncologic Drugs Advisory Committee (ODAC).